Researcher
Tom Vanden Berghe
- Disciplines:Biophysics, Molecular and cell biology, Laboratory medicine, Microbiology, Systems biology, Plant biology, Medicinal and biomolecular chemistry
Affiliations
- Department of Biomedical molecular biology (Department)
Member
From1 Oct 1999 → Today
Projects
1 - 5 of 5
- Investigating the immunoregulatory properties of ferroptosis in experimental cancer modelsFrom1 Nov 2020 → 31 Oct 2024Funding: FWO fellowships
- Therapeutic exploration of lead ferroptosis inhibitors in multiple sclerosis - grant 2020From1 Jan 2020 → 30 Jun 2021Funding: Foundations, funds and other with scientific goal
- Therapeutic exploration of lead ferroptosis inhibitors in multiple sclerosisFrom1 Jan 2019 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
- Nanoparticle-based ferroptosis-induction tot treat neuro-and glioblastomaFrom1 Jan 2019 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
- Study of the in vivo role of effector caspases (patho-) physiological model systems.From1 Oct 2007 → 30 Sep 2013Funding: BOF - Other initiatives, FWO fellowships
Publications
1 - 10 of 113
- Therapeutic exploitation of ferroptosis(2024)
Authors: Magali Walravens, Ine Koeken, Tom Vanden Berghe
Pages: 693 - 706 - Ferroptosis in health and disease(2024)
Authors: Carsten Berndt, Hamed Alborzinia, Vera Skafar Amen, Scott Ayton, Uladzimir Barayeu, Alexander Bartelt, Hülya Bayir, Christina M Bebber, Kivanc Birsoy, Jan P Böttcher, et al.
- Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD)(2024)
Authors: Claudia Theys, Tineke Vanderhaeghen, Evelien Van Dijck, Cedric Peleman, Anne Scheepers, Joe Ibrahim, Ligia Mateiu, Steven Timmermans, Tom Vanden Berghe, Sven M. Francque, et al.
- Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease(2024)
Authors: Cédric Peleman, Stig Hellemans, Geraldine Veeckmans, Wout Arras, Hao Zheng, Ine Koeken, Emily Van San, Behrouz Hassannia, Magali Walravens, Edissa Kayirangwa, et al.
Pages: 1113 - 1126 - Improving cardiac differentiation of human pluripotent stem cells by targeting ferroptosis(2024)
Authors: Jeffrey Aalders, Laurens Léger, Behrouz Hassannia, Vera Goossens, Tom Vanden Berghe, Jolanda van Hengel
Pages: 21 - 31 - Apoptotic cell death in disease : current understanding of the NCCD 2023(2023)
Authors: Ilio Vitale, Federico Pietrocola, Emma Guilbaud, Stuart A Aaronson, John M Abrams, Dieter Adam, Massimiliano Agostini, Patrizia Agostinis, Emad S Alnemri, Lucia Altucci, et al.
Pages: 1097 - 1154 - Beyond ferrostatin-1 : a comprehensive review of ferroptosis inhibitors(2023)
Authors: Camilla Scarpellini, Greta Klejborowska, Caroline Lanthier, Behrouz Hassannia, Tom Vanden Berghe, Koen Augustyns
Pages: 902 - 916 - Therapeutic exploration of ferroptosis in multiple sclerosis(2023)
Authors: Emily Van San, Tom Vanden Berghe, Peter Vandenabeele
- Caspase inhibition modulates monocyte-derived macrophage polarization in damaged tissues(2023)
Authors: Stéphanie Solier, Michele Mondini, Lydia Meziani, Arnaud Jacquel, Catherine Lacout, Tom Vanden Berghe, Yvon Julé, Jean-Claude Martinou, Gérard Pierron, Julie Rivière, et al.
- Ferroptosis and pyroptosis signatures in critical COVID-19 patients(2023)
Authors: Cédric Peleman, Samya Van Coillie, Symen Ligthart, Sze Men Choi, Jan De Waele, Pieter Depuydt, Dominique Benoit, Hannah Schaubroeck, Sven M. Francque, Karolien Dams, et al.
Pages: 2066 - 2077
Patents
1 - 6 of 6
- COMPOUNDS FOR INHIBITING CELL DEATH (Inventor)
- COMPOUNDS FOR INHIBITING CELL DEATH (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- COMPOUNDS FOR INHIBITING CELL DEATH (Inventor)
- Targeting of Interleukin-1 and -18 in treatment of septic shock (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)